The sclerostin-bone protein interactome

Biochemical and Biophysical Research Communications

Volumn 417, Issue 2, 2012, Pages 830-835

  Devarajan Ketha, Hemamalini ^a   Craig, Theodore A ^a   Madden, Benjamin J ^a   Robert Bergen, H ^a,b   Kumar, Rajiv ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Bone formation; Bone resorption; Protein affinity chromatography; Protein interaction; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM BINDING PROTEIN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE I; CASEIN KINASE I; CASEIN KINASE II; COLLAGEN; DODECYL SULFATE SODIUM; FETUIN A; FOLLISTATIN; GLUCOSE 6 PHOSPHATE ISOMERASE; GLYCOGEN PHOSPHORYLASE; GRANZYME; GREMLIN 1; HISTONE H2A; HISTONE H2B; LIPOCORTIN 1; LIPOCORTIN 2; MALTOSE BINDING PROTEIN; MIDKINE; MYOSIN; MYOSIN VIIA; NEUROPILIN; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEIN S 100; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 4; SODIUM CHLORIDE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BONE METABOLISM; MASS SPECTROMETRY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN ISOLATION; RAT; WNT SIGNALING PATHWAY;

ALKALINE PHOSPHATASE; AMYLOSE; ANIMALS; BONE AND BONES; BONE DEMINERALIZATION TECHNIQUE; BONE MORPHOGENETIC PROTEINS; CASEIN KINASE II; CHROMATOGRAPHY, AFFINITY; GENETIC MARKERS; HUMANS; PROTEIN INTERACTION MAPPING; PROTEOME; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84855857774     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.048     Document Type: Article

References (52)

1. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22:6267-6276.
2. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., Van Den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 2001, 10:537-543.
3. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 2002, 39:91-97.
4. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D., Hamersma H., Beighton P., Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 2001, 68:577-589.
5. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., Gardner J.C., Galas D., Schatzman R.C., Beighton P., Papapoulos S., Hamersma H., Brunkow M.E. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 2002, 110:144-152.
6. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 2011, 26:19-26.
7. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., Kurahara C., Gao Y., Cao J., Gong J., Asuncion F., Barrero M., Warmington K., Dwyer D., Stolina M., Morony S., Sarosi I., Kostenuik P.J., Lacey D.L., Simonet W.S., Ke H.Z., Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 2008, 23:860-869.
8. Kronenberg H.M. Developmental regulation of the growth plate. Nature 2003, 423:332-336.
9. Reddi A.H. Bone and cartilage differentiation. Curr. Opin. Genet. Dev. 1994, 4:737-744.
10. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 2002, 346:1513-1521.
11. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M., Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G., Apte S., Adkins W.N., Allgrove J., Arslan-Kirchner M., Batch J.A., Beighton P., Black G.C., Boles R.G., Boon L.M., Borrone C., Brunner H.G., Carle G.F., Dallapiccola B., De Paepe A., Floege B., Halfhide M.L., Hall B., Hennekam R.C., Hirose T., Jans A., Juppner H., Kim C.A., Keppler-Noreuil K., Kohlschuetter A., LaCombe D., Lambert M., Lemyre E., Letteboer T., Peltonen L., Ramesar R.S., Romanengo M., Somer H., Steichen-Gersdorf E., Steinmann B., Sullivan B., Superti-Furga A., Swoboda W., van den Boogaard M.J., Van Hul W., Vikkula M., Votruba M., Zabel B., Garcia T., Baron R., Olsen B.R., Warman M.L. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
12. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X., Adair R., Chee L., FitzGerald M.G., Tulig C., Caruso A., Tzellas N., Bawa A., Franklin B., McGuire S., Nogues X., Gong G., Allen K.M., Anisowicz A., Morales A.J., Lomedico P.T., Recker S.M., Van Eerdewegh P., Recker R.R., Johnson M.L. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 2002, 70:11-19.
13. Winkler D.G., Sutherland M.S., Ojala E., Turcott E., Geoghegan J.C., Shpektor D., Skonier J.E., Yu C., Latham J.A. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J. Biol. Chem. 2005, 280:2498-2502.
14. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., Thesleff I., Itoh N. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J. Biol. Chem. 2003, 278:24113-24117.
15. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., Krumlauf R. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 2006, 21:1738-1749.
16. Kamiya N., Ye L., Kobayashi T., Mochida Y., Yamauchi M., Kronenberg H.M., Feng J.Q., Mishina Y. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008, 135:3801-3811.
17. van Bezooijen R.L., Roelen B.A., Visser A., van derWee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S.E., ten Dijke P., Lowik C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004, 199:805-814.
18. van Bezooijen R.L., Svensson J.P., Eefting D., Visser A., van der Horst G., Karperien M., Quax P.H., Vrieling H., Papapoulos S.E., ten Dijke P., Lowik C.W. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J. Bone Miner. Res. 2007, 22:19-28.
19. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 2005, 280:26770-26775.
20. Craig T.A., Bhattacharya R., Mukhopadhyay D., Kumar R. Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem. Biophys. Res. Commun. 2010, 392:36-40.
21. Craig T.A., Kumar R. Sclerostin-erbB-3 interactions: modulation of erbB-3 activity by sclerostin. Biochem. Biophys. Res. Commun. 2010, 402:421-424.
22. Olsen J.V., deGodoy L.M., Li G., Macek B., Mortensen P., Pesch R., Makarov A., Lange O., Horning S., Mann M. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Molecular & cellular proteomics: MCP 2005, 4:2010-2021.
23. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74:5383-5392.
24. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75:4646-4658.
25. Craig T.A., Sommer S.L., Beito T.G., Kumar R. Production and characterization of monoclonal antibodies to human sclerostin. Hybridoma (Larchmt) 2009, 28:377-381.
26. Wilson J.L., Scott I.M., McMurry J.L. Optical biosensing: kinetics of protein A-IGG binding using biolayer interferometry. Biochem. Mol. Biol. Educ. 2010, 38:400-407.
27. Chen B., Blair D.G., Plisov S., Vasiliev G., Perantoni A.O., Chen Q., Athanasiou M., Wu J.Y., Oppenheim J.J., Yang D. Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J. Immunol. 2004, 173:5914-5917.
28. Eijken M., Swagemakers S., Koedam M., Steenbergen C., Derkx P., Uitterlinden A.G., van der spek P.J., Visser J.A., de Jong F.H., Pols H.A., van Leeuwen J.P. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007, 21:2949-2960.
29. Quan J.X., Zheng F., Li X.X., Hu L.L., Sun Z.Y., Jiao Y.L., Wang B.L. Cloning and analysis of rat osteoclast inhibitory lectin gene promoter. J. Cell. Biochem. 2009, 106:599-607.
30. Gazzerro E., Pereira R.C., Jorgetti V., Olson S., Economides A.N., Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 2005, 146:655-665.
31. Chen X.D., Fisher L.W., Robey P.G., Young M.F. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. 2004, 18:948-958.
32. Tomoeda M., Yamada S., Shirai H., Ozawa Y., Yanagita M., Murakami S. PLAP-1/asporin inhibits activation of BMP receptor via its leucine-rich repeat motif. Biochem. Biophys. Res. Commun. 2008, 371:191-196.
33. Iemura S., Yamamoto T.S., Takagi C., Uchiyama H., Natsume T., Shimasaki S., Sugino H., Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc. Natl. Acad. Sci. USA 1998, 95:9337-9342.
34. Balemans W., Piters E., Cleiren E., Ai M., Van Wesenbeeck L., Warman M.L., Van Hul W. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif. Tissue Int. 2008, 82:445-453.
35. Gao Y., Wang H.Y. Casein kinase 2 is activated and essential for Wnt/beta-catenin signaling. J. Biol. Chem. 2006, 281:18394-18400.
36. Nusse R. Cell biology: relays at the membrane. Nature 2005, 438:747-749.
37. Satow R., Shitashige M., Jigami T., Honda K., Ono M., Hirohashi S., Yamada T. Traf2- and Nck-interacting kinase is essential for canonical Wnt signaling in Xenopus axis formation. J. Biol. Chem. 2010, 285:26289-26294.
38. Shitashige M., Satow R., Jigami T., Aoki K., Honda K., Shibata T., Ono M., Hirohashi S., Yamada T. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res. 2010, 70:5024-5033.
39. Holmes G., Niswander L. Expression of slit-2 and slit-3 during chick development. Dev. Dyn. 2001, 222:301-307.
40. Kirsch T. Annexins - their role in cartilage mineralization. Front. Biosci. 2005, 10:576-581.
41. Basel D., Steiner R.D. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet. Med. 2009, 11:375-385.
42. Malone A.M., Anderson C.T., Tummala P., Kwon R.Y., Johnston T.R., Stearns T., Jacobs C.R. Primary cilia mediate mechanosensing in bone cells by a calcium-independent mechanism. Proc. Natl Acad. Sci. USA 2007, 104:13325-13330.
43. Balcerzak M., Hamade E., Zhang L., Pikula S., Azzar G., Radisson J., Bandorowicz-Pikula J., Buchet R. The roles of annexins and alkaline phosphatase in mineralization process. Acta Biochim. Pol. 2003, 50:1019-1038.
44. Gay C.V., Mueller W.J. Carbonic anhydrase and osteoclasts: localization by labeled inhibitor autoradiography. Science 1974, 183:432-434.
45. Sly W.S., Hewett-Emmett D., Whyte M.P., Yu Y.S., Tashian R.E. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc. Natl. Acad. Sci. USA 1983, 80:2752-2756.
46. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium, Nat Genet 11 (1995) 130-136.
47. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., Zelenchuk L., Evdokiou A., Findlay D.M. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Miner. Res. 2011, 26:1425-1436.
48. Xiao Z.S., Crenshaw M., Guo R., Nesbitt T., Drezner M.K., Quarles L.D. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am. J. Physiol. 1998, 275:E700-708.
49. Bragdon B., Thinakaran S., Moseychuk O., Gurski L., Bonor J., Price C., Wang L., Beamer W.G., Nohe A. Casein kinase 2 regulates in vivo bone formation through its interaction with bone morphogenetic protein receptor type Ia. Bone 2011, 49:944-954.
50. Price P.A., Caputo J.M., Williamson M.K. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. J. Bone Miner. Res. 2002, 17:1171-1179.
51. Rosen V. BMP and BMP inhibitors in bone. Ann. N. Y. Acad. Sci. 2006, 1068:19-25.
52. Mitsiadis T.A., Muramatsu T., Muramatsu H., Thesleff I. Midkine (MK), a heparin-binding growth/differentiation factor, is regulated by retinoic acid and epithelial-mesenchymal interactions in the developing mouse tooth, and affects cell proliferation and morphogenesis. J. Cell Biol. 1995, 129:267-281.